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infant in comparison to no-screening strategy. Transferred to the entire birth cohort 
newborn screening is able to reduce total costs by 14 million € from the Austrian 
health care systems perspective each year. ConClusions: Funding the new-born 
screening saves money and is cost-effective for the Austrian health care system.
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objeCtives: When patients start their first injectable therapy, clinicians can choose 
between glucagon-like peptide-1 (GLP-1) agonists and basal insulins. This study 
investigates the cost-effectiveness of exenatide once weekly (Bydureon®), a GLP-1 
agonist, compared with insulin glargine in patients inadequately controlled with 
metformin (±sulfonylureas) based on long-term clinical evidence. Methods: The 
validated CARDIFF model was used to conduct the analyses. Clinical inputs were 
derived from a randomized clinical trial and a 3-year follow-up study of it comparing 
exenatide once weekly (ExQW) versus insulin glargine once daily. Based on these clini-
cal inputs and the United Kingdom Prospective Diabetes Study (UKPDS) equations, 
the model predicts disease progression and the number of micro- and macro-vascular 
complications, along with diabetes-specific and all-cause mortality. The perspective 
of the National Health Service in the UK was adopted over a lifetime horizon. Local 
unit costs and utility data were assigned to the appropriate model parameters to 
calculate total Quality-Adjusted-Life-Years (QALYs) and total costs. Deterministic 
and probabilistic sensitivity analyses (PSA) were conducted. Results: Long-term 
treatment with ExQW was well tolerated and associated with sustained glycaemic 
control and sustained weight loss over at least 3 years. Compared to glargine, ExQW 
in combination with metformin was associated with an incremental benefit of 0.123 
QALYs (95%CI: 0.057; 0.178) at an additional cost of £1,722 (95%CI: £1,396; £2,089), 
resulting in an incremental cost-effectiveness ratio of £13,967 per QALY gained. The 
PSA showed that at a willingness-to-pay threshold of £20,000 per QALY gained, ExQW 
treatment had an 83% probability to be cost-effective compared to the strategy includ-
ing glargine. Sensitivity analyses showed that results were robust to variation in 
model parameters that carry uncertainty. ConClusions: Exenatide once weekly in 
combination with metformin was shown to be a cost-effective treatment option as 
first injectable therapy in patients inadequately controlled with metformin within 
established UK cost-effectiveness thresholds.
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objeCtives: To update the cost-effectiveness of dapagliflozin (Forxiga®), a selective 
sodium-glucose co-transporter-2 (SGLT-2) inhibitor, compared with a sulphonylurea 
(SU) when added to metformin in patients inadequately controlled with metformin 
mono-therapy based on long-term clinical evidence. Methods: The published 
and validated CARDIFF diabetes model was used to conduct the analyses. Clinical 
inputs were derived from a 4-year follow-up study of a randomized clinical trial 
comparing dapagliflozin and glipizide in combination with metformin. Based on 
these clinical inputs and the United Kingdom Prospective Diabetes Study (UKPDS) 
equations, the model predicts disease progression and the number of micro- and 
macro-vascular complications, along with diabetes-specific and all-cause mor-
tality. The perspective of the National Health Service in England and Wales was 
adopted over a lifetime horizon. Local unit costs and utility data were assigned to 
the appropriate model parameters to calculate total Quality-Adjusted-Life-Years 
(QALYs) and total costs. Deterministic and probabilistic sensitivity analyses (PSA) 
were conducted. Results: Dapagliflozin showed greater durability of HbA1c reduc-
tion compared with SU and sustained weight loss over 4 years. Compared to SU 
added on top of metformin, dapagliflozin add-on to metformin was associated with 
an incremental benefit of 0.181 QALYs (95%CI: 0.088; 0.268) at an additional cost of 
£819 (95%CI: £415; £1,259), resulting in an ICER point estimate of £4,521 per QALY 
gained. The univariate analyses showed that no input parameter change inflated the 
ICER above £15,000 per QALY. The PSA showed that at a willingness-to-pay threshold 
of £20,000 per QALY gained, dapagliflozin treatment had an estimated 100% prob-
ability to be cost-effective compared to an SU treatment strategy. These findings 
were shown to be robust with all sensitivity analyses. ConClusions: Dapagliflozin 
in combination with metformin was shown to be a cost-effective treatment option 
for patients who are inadequately controlled with metformin mono-therapy within 
established UK cost-effectiveness thresholds.
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objeCtives: To evaluate the cost-effectiveness of canagliflozin in dual therapy as 
add-on to metformin compared to sitagliptin and in triple therapy as add-on to met-
formin (MET) and sulfonylurea (SU) compared to sitagliptin. Methods: The IMS 
CORE Diabetes Model was used to evaluate the cost-effectiveness of canagliflozin 
100 mg and 300 mg versus sitagliptin 100 mg using data from both clinical trials and 
network meta-analysis, combined with Portuguese-specific data when available. The 
perspective of the analysis is societal in accordance with Guidelines for Economic 
Drug Evaluation Studies from INFARMED. Results: The cost-effectiveness analyses 
indicate that canagliflozin (100 mg and 300 mg weighted average 65: 35) is cost-saving 
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objeCtives: To estimate the short-term cost-effectiveness of insulin detemir 
compared with Neutral Protamine Hagedorn (NPH) insulin when initiating insulin 
treatment in patients with Type 2 Diabetes Mellitus (T2DM) in Spain. Methods: A 
short-term (1 year) cost-effectiveness model was adapted to the Spanish public health 
care system. Based on a head-to-head randomized controlled trial (NCT00104182) 
that showed similar efficacy in glycemic control for both insulin types, weight gain 
(Δ = 0.9Kg) and the rate of non-severe hypoglycemia (between-arms RR= 0.52; IC95% 
0.44-0.61) of detemir vs. NPH were selected as clinical outcomes. Costs (Euros 2014) 
were estimated from the perspective of the Spanish national health system and 
derived from national public sources. Only insulin treatment and management costs 
associated with non-severe hypoglycemic episodes were included in the analysis. 
According to a published study, non-severe hypoglycemia (a self-managed event) 
was assumed to imply the use of 5.3 glucometer strips and a visit to a general practi-
tioner for 25% of patients (Orozco-Beltrán et al., 2014). The disutility value associated 
to weight gain was -0.0100 per BMI unit (Lee et al., 2005). The disutility associated to 
daytime and nocturnal non-severe hypoglycemia was -0.0041 and -0.0067 per event, 
respectively (Evans et al., 2013). Results: The yearly gain in quality-adjusted life 
years (QALY) associated to insulin detemir versus NPH was 0.015. The estimated 
incremental cost of treating patients with insulin detemir versus NPH was € 244.03. 
The incremental cost-effectiveness ratio (ICER) of insulin detemir versus NPH in 
insulin-naïve T2DM patients was estimated to be € 16,381.18/QALY in Spain. This 
value is lower than those published for other European countries (€ 21,768-28,349/
QALY) and is beneath the ICER threshold commonly accepted for Spain (€ 30,000/
QALY). ConClusions: Insulin detemir is a cost-effective alternative to NPH insulin in 
the first and subsequent years of treatment of insulin-naïve T2DM patients in Spain.
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objeCtives: To estimate the short-term cost-effectiveness of insulin detemir 
compared with Neutral Protamine Hagedorn (NPH) insulin when initiating insulin 
treatment in patients with Type 1 Diabetes Mellitus (T1DM) in Spain. Methods: A 
short-term (1 year) cost-effectiveness model was adapted to the Spanish public health 
care system. Based on the Update of CADTH Technology Report No. 92 (2008) that 
showed similar efficacy in glycemic control for both insulin types, the rate of hypo-
glycemia with detemir vs. NPH (RR= 0.84; IC95% 0.74-0.97) was the considered clinical 
outcome. Costs, expressed in Euros 2014, were estimated from the perspective of the 
Spanish national health system and derived from national health care cost databases 
and publications. Only insulin treatment and management costs associated with 
non-severe hypoglycemic episodes were included in the analysis. Non-severe hypo-
glycemia, defined as a self-managed event, was assumed to imply the use of extra 5.3 
glucometer strips during the following week and a visit to a general practitioner for 
25% of patients (Orozco-Beltrán et al., 2014). The disutility associated to daytime and 
nocturnal non-severe hypoglycemia was -0.0041 and -0.0067 per event, respectively 
(Evans et al., 2013). Results: The gain in quality-adjusted life years (QALY) associated 
to determir versus NPH was 0.108. The estimated incremental cost of determir versus 
NPH was € 247.40. The incremental cost-effectiveness ratio (ICER) of detemir vs. NPH 
in patients with T1DM was estimated to be € 2,286.67/QALY in Spain. This value is 
significantly lower than those reported for other European countries (€ 10,938-13,310/
QALY) and are much lower than the ICER threshold commonly accepted for Spain 
(€ 30,000/QALY). ConClusions: Detemir is a cost-effective alternative to NPH insulin 
in the first year of treatment of insulin-naive T1DM patients in Spain.
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objeCtives: Since more than 45 years, a preventive program for the detection of 
congenital metabolic and endocrine diseases is carried out successfully in Austria. The 
goal is to investigate every new-born a few days after birth to initiate a quality assured 
therapy as quickly as possible. Since 1966, this program is carried out by the Federal 
Ministry of Health at the University Clinic for Child and Adolescent Medicine, Medical 
University of Vienna. The aim of this study was to determine cost-effectiveness of 
the new-born screening. Methods: We developed a decision-analytic model, which 
include specific Markov processes for the core disorders: Cystic Fibrosis (CF), phe-
nylketonuria (PKU), medium-chain acyl-CoA (MCAD), congenital hypothyroidism (CH), 
galactosemia (GAL) and Maple syrup urine disease (MSUD). Costs and health benefits 
were estimated for a cohort of new-borns in Austria in 1 year. The analysis focused 
on lifetime consequences. This encompassed direct costs (including screening costs 
and cost of illness), quality-adjusted-life-years (QALYs) and reduced expectation of 
life. Costs were presented per child and for the Austrian birth cohort. Costs from 
published sources were used (2014 Euro) from the health care systems perspective. 
QALYs, life-years (LYs) and costs were projected over a life-time horizon and dis-
counted at 3% p. a. Results: We found ten-times higher lifetime costs per child 
without screening compared to screening. The incremental costs of screening ranged 
from 12.308 € (MCAD) to 291.332 € (PKU). Screening saved 181 € and 0.09 QALYs per 
